María J. Cejalvo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
María J. Cejalvo has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Javier de la Rubia
Servicio de Hematología y Hemoterapia, Hospital Universitario y Politécnico La Fe, Valencia, España; Universidad Católica de Valencia San Vicente Mártir, Valencia, España; Instituto de Investigación Sanitaria La Fe, Valencia, España
1 shared publication - Mario A. Legarda
Hematology Department, University Hospital Doctor Peset, 46017 Valencia, Spain
1 shared publication
Latest Publications
- Open Access
Recent Advances in the Treatment of Patients with Multiple Myeloma
In the past 20 years, few diseases have seen as great progress in their treatment as multiple myeloma. With the approval of many new drugs and the limited availability of clinical trials comparing head-to-head the different possible combinations, the choice of the best treatments at each stage of the disease becomes complex as well as crucial since multiple myeloma remains incurable. This article presents a general description of the novelties of the whole treatment of multiple myeloma, from induction in the newly diagnosed patient through the role of hematopoietic stem cell transplantation and maintenance treatment until early and late relapses, including a section on recently approved drugs as well as novel drugs and immunotherapy in advanced stages of research, and that will surely play a relevant role in the treatment of this devastating disease in the coming years.
Open AccessRecent Advances in the Treatment of Patients with Multiple Myeloma
In the past 20 years, few diseases have seen as great progress in their treatment as multiple myeloma. With the approval of many new drugs and the limited availability of clinical trials comparing head-to-head the different possible combinations, the choice of the best treatments at each stage of the disease becomes complex as well as crucial since multiple myeloma remains incurable. This article presents a general description of the novelties of the whole treatment of multiple myeloma, from induction in the newly diagnosed patient through the role of hematopoietic stem cell transplantation and maintenance treatment until early and late relapses, including a section on recently approved drugs as well as novel drugs and immunotherapy in advanced stages of research, and that will surely play a relevant role in the treatment of this devastating disease in the coming years.